Placeholder Banner

Member Benefits by Sector: Startups

BIO recognizes the unique needs of emerging companies and helps you achieve your goals. From advocating for pro-innovation tax policies to encouraging an economic and policy environment to foster investment, we focus on critical issues affecting smaller companies and build programs to enhance your development.

Washington DC Capitol Dome
Finance and Tax

BIO advocates on behalf of our members on issues related to taxes, financial services, securities, and accounting policies that impact companies and biotech capital formation.  Areas of interest include the JOBS Act, Sarbanes-Oxley (SOX) Section 404(b), proxy advisory firms, short selling transparency, market structure reform, tick size, accounting and auditing standards, and SEC life science reporting topics. 

Committee on Foreign Investment in the U.S.

BIO works to engage the Committee on Foreign Investment in the U.S. (CFIUS) in it's rulemaking process to avoid an undue impact on the biotechnology sector's ability to enter into global research partnerships and attract foreign investments.

US Department of the Treasury
BIO One-on-One Partnering

BIO recognizes the need for capital and collaboration faced by startups.  Therefore we host more than a dozen events throughout the year to help small biotechs connect with potential investors, licensors, and partners. BIO members receive discounts on registration, presentation, and exhibition fees at BIO events.

Get Involved!

Our members drive our advocacy. Consider joining a BIO committee today to help shape our policy work.

Why Join BIO?
Dr. Nancy Simonian, President & CEO Syros Pharmaceuticals
Dr. Nancy Simonian, President & CEO Syros Pharmaceuticals

Explore webinars, BIO panels, comments, and more on this members only site.

BIO One-on-One Partnering

Meet key partners to grow your business at our events around the world.


Join fellow BIO members on Capitol Hill and talk with Members of Congress.

Member Spotlight - Marc Belsky

“Our ability to affect change through our involvement on the Finance and Tax Committee at BIO has been extremely beneficial to us as a small cap public biotech company. In particular, BIO was able to add a revenue requirement for SOX 404(b) qualification. Accordingly, along with our other small cap biotech peers, we will be able to further delay implementing this costly and burdensome regulation."

Marc Belsky
Chief Financial Officer
Kezar Life Sciences

Join BIO Today

Join BIO today to get involved in our advocacy work, save money through BIO Business Solutions, and to make the most of events and educational opportunities.